Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SK pharmteco, AaviGen Enter Strategic Gene Therapy Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

SK pharmteco, AaviGen Enter Strategic Gene Therapy Mfg. Pact

SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SK pharmteco, a global CDMO for small molecules and advanced therapies, and AaviGen GmbH, a preclinical stage biotechnology company focused curative gene therapies for cardiovascular and cardiopulmonary diseases, entered a multi-year manufacturing agreement wherein SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure. 
 
AaviGen’s heart-specific adeno-associated viral vector technology enables the development of therapies that target and reverse the underlying molecular causes of heart muscle dysfunction. By focusing on key areas such as cardioprotection, contractility, and energy metabolism, AaviGen aims to improve patient outcomes and restoring normal cardiac function. 
 
“SK pharmteco is a key partner for AaviGen as part of our strategy to develop and commercialize innovative gene therapies against diseases of the cardiovascular and cardiovascular system,” said Patrick Most, CEO of AaviGen. “The SK pharmteco team offered the trust, competence, and understanding of how a young company like AaviGen must operate in a dynamic market from the first minute of our interactions. We look forward to the collaboration with great confidence.” 
  
“We are thrilled to partner with AaviGen on their innovative gene therapy for heart failure,” said Patrick Mahieux, SK pharmteco’s President of Cell and Gene, Europe. “Our deep expertise in viral vector manufacturing and our commitment to quality and efficiency make us the ideal partner to support the development and commercialization of this promising therapy. We look forward to contributing to the advancement of this groundbreaking treatment for patients in need.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics